Abstract Number: 2867 • 2019 ACR/ARP Annual Meeting
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the…Abstract Number: 1756 • 2019 ACR/ARP Annual Meeting
Health-related Social Media Use by Parents of Children with Rheumatic Diseases
Background/Purpose: Disease and treatment burdens are high for children living with rheumatic diseases. Pediatric patients and their families lack a mature evidence base to guide…Abstract Number: 465 • 2018 ACR/ARHP Annual Meeting
Seasonal Variation in Cutaneous Flares for Pediatric Lupus
Background/Purpose: Exposure to sunlight has been proposed as a possible environmental trigger for lupus flares, particularly cutaneous disease. Contradictory findings exist regarding seasonal variation in…Abstract Number: 466 • 2018 ACR/ARHP Annual Meeting
Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR
Background/Purpose: Streptococcus pneumonia is a leading cause of illness in children worldwide and can lead to death in those with an immunosuppressed status. Given the…Abstract Number: 914 • 2018 ACR/ARHP Annual Meeting
Increased Adverse Childhood Experiences in Children with Arthritis: An Analysis of the National Survey of Children’s Health
Background/Purpose: Adverse Childhood Experiences (ACEs) are associated with increased risk of chronic disease and poorer health in children and adults. Emerging data suggest an association…Abstract Number: 1422 • 2018 ACR/ARHP Annual Meeting
Impact of Juvenile Localized Scleroderma on Longitudinal Quality of Life
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic autoimmune disease, with cutaneous and extra-cutaneous manifestations (ECM) requiring long-term immunosuppressive therapy. Few studies have evaluated the…Abstract Number: 1438 • 2018 ACR/ARHP Annual Meeting
Treatment and Response of Down Syndrome Arthropathy
Background/Purpose: Of the very few studies describing Down syndrome arthropathy (DA), crude prevalence estimates indicate DA maybe as common as juvenile idiopathic arthritis (JIA), however,…Abstract Number: 1850 • 2018 ACR/ARHP Annual Meeting
A Population Based Study of High School Academic Outcomes in Individuals with Childhood-Onset Chronic Rheumatic Diseases in Manitoba, Canada
Background/Purpose: Childhood-onset chronic rheumatic diseases (ChildCRD) are rheumatic diseases with onset <18 years old, including juvenile arthritis (JA) and systemic autoimmune rheumatic diseases (SARD). ChildCRD…Abstract Number: 2034 • 2018 ACR/ARHP Annual Meeting
Increased Invasive Capacity and Metabolic Activity in Synovial Fibroblasts from Children with Downs Arthropathy Compared to Juvenile Idiopathic Arthritis
Background/Purpose: Downs Arthropathy (DA) is an inflammatory joint condition affecting children with Down syndrome, which is under-recognised, has a delayed diagnoses, resulting in chronic disability.…Abstract Number: 2403 • 2018 ACR/ARHP Annual Meeting
The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study
Background/Purpose: The therapeutic compliance (TC) is a major issue for the management of Juvenile Idiopathic Arthritis (JIA). The chronic nature of this inflammatory rheumatism requires…Abstract Number: 2404 • 2018 ACR/ARHP Annual Meeting
Quality of Life Assessment in Juvenile Idiopathic Arthritis: A Single Center Assessment
Background/Purpose: Patients with Juvenile Idiopathic Arthritis (JIA) face physical, social, and emotional issues that affect their quality of life. Health-related quality of life (HRQoL) is…Abstract Number: 1285 • 2017 ACR/ARHP Annual Meeting
Extracutaneous Involvement Is Common in Juvenile Localized Scleroderma and Associated with a Higher Level of Perceived Disease Impact
Background/Purpose: Juvenile localized scleroderma (jLS) is often associated with deep tissue and extracutaneous involvement (ECI), putting children at risk for severe morbidity such as hemiatrophy,…Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting
Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study
Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…Abstract Number: 1728 • 2017 ACR/ARHP Annual Meeting
Interferon Gamma (IFN-γ) Subpopulations in Skin Homing T Cells of Localized Scleroderma
Background/Purpose: Localized scleroderma (LS) has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue. The understanding of the pathophysiology…Abstract Number: 2252 • 2017 ACR/ARHP Annual Meeting
Initial Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) in Children with Juvenile Myositis
Background/Purpose: Juvenile myositis (JM) can worsen quality of life (QoL) via proximal weakness, rashes, and treatments side effects. QoL legacy instruments may be limited by…
- « Previous Page
- 1
- …
- 55
- 56
- 57
- 58
- 59
- …
- 62
- Next Page »